European Pharmaceutical Review Issue 4 2020

Within this issue find articles on the complexities of sterility assurance, how to detect and eliminate the risk of NDMA contamination and the findings from a study involving a novel formulation of cannabinoids that has been developed to treat glioblastoma. Also included are articles on the opportunities blockchain provides for life science and healthcare businesses, as well as a discussion on how COVID-19 has impacted life sciences and biotech investment and its potential effect on investor behaviour as the pandemic subsides.


Find in the issue:

    The trials and tribulations of the medical devices and IVD regulations
    Paul Ranson, Morgan Lewis
    Developing a preventive vaccine regimen to tackle Ebola
    Johan Van Hoof, Janssen Vaccines
    Regenerative medicine: a manufacturing overview
    Maciej Nakoniecznik, University College London
    Overview of workflows and data approaches in bioproduction – an industry perspective
    Melanie Diefenbacher, Genedata
    A glimpse at how Novartis’ manufacturing and supply organisation responded to COVID-19
    Steffen Lang, Novartis
    Beyond compliance: why embracing the FMD can transform medicine supply chain thinking
    Sébastien Sliski, Zetes

The rest of this content is restricted - login or subscribe free to access

Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here